Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
$Viking Therapeutics (VKTX.US)$ shares are rising Thursday after the biotech company announced plans to advance its experimental weight loss drug to late-stage trials.
$Viking Therapeutics (VKTX.US)$這家生物技術公司宣佈計劃將其實驗性減重藥推進到後期試驗後，股價正在上漲。
After the market close on Wednesday, Viking Therapeutics reported financial results for the second quarter that included an update on VK2735, the lead candidate of the company's unique series of novel dual agonists of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of obesity.
週三收盤後，維京治療公司發佈了第二季度的財務業績報告，其中包括該公司一系列新型雙重激動劑——Viking Therapeutics GLP-1受體和胰高糖素依賴性多肽（GIP）受體的主要候選物VK2735的最新消息，以期將其用於潛在的肥胖治療。
Viking said earlier this year that it expected to start another mid-stage trial for VK2735, but announced late Wednesday that it would move the weekly injection into a Phase 3 trial. Viking shares popped on the news, while shares of $Eli Lilly and Co (LLY.US)$ and $Novo-Nordisk A/S (NVO.US)$ fell. Viking is one of several companies racing to capture market share in the GLP-1 market, currently being led by Lilly and Novo Nordisk.
維京公司今年早些時候表示，他們預計將爲VK2735啓動另一項中期試驗，但週三晚間宣佈將每週一次的注射轉入到第3階段的試驗中。維京公司的股票因此消息上漲，而其他公司的股票則下跌。維京是幾家公司之一，爭取在GLP-1市場上佔據市場份額，目前這一市場由Lilly和諾和諾德領導。$禮來 (LLY.US)$和頁面。$諾和諾德 (NVO.US)$維京公司是幾家公司之一，正在賽跑中爭取在GLP-1市場佔據市場份額，目前這一市場由Lilly和諾和諾德領導。
Viking said it received feedback from the U.S. Food and Drug Administration (FDA) based on a Type C meeting packet it submitted to the agency earlier this year. After reviewing the feedback, the company decided to advance VK2735 into late-stage trials for obesity.
Viking表示，它根據今年早些時候向美國食品和藥物管理局（FDA）提交的C類型會議文件收到了的反饋意見。在審查這些反饋意見之後，該公司決定將VK2735引入用於肥胖的後期試驗。
"The Phase 2 VENTURE study of VK2735 in obesity demonstrated up to an approximately 15% reduction in body weight from baseline following 13 weeks of dosing, as well as promising safety and tolerability. Following receipt of written feedback from an FDA Type C meeting, we are advancing this compound into Phase 3 development," said Brian Lian, CEO of Viking Therapeutics.
“VK2735在肥胖症的第二階段創業研究中顯示出從基線開始的體重下降高達15％的降幅，以及令人滿意的安全性和耐受性。在接到FDA C型會議的書面反饋後，我們將把這個compound推進到第三階段研發，”維京治療公司CEO Brian Lian表示。
Viking expects to schedule an end-of-Phase 2 meeting with the FDA later this year. The company noted that details on the Phase 3 trial design and timing will be disclosed following the end-of-Phase 2 meeting.
Viking預計在今年晚些時候安排第二階段結束會議。該公司指出，關於第3階段試驗的設計和時間表將在第二階段結束會議後披露。
On the conference call late Wednesday, Lian said the company plans to test VK2735 as a monthly injection in future studies. The company also said the oral tablet version of VK2735 demonstrated encouraging signs in early trials, with up to 5.3% weight loss after 28 days. Viking expects to initiate a Phase 2 trial for the oral program later this year.
在週三的電話會議上，Lian表示，該公司計劃在未來的研究中將VK2735作爲每月一次的注射。該公司還表示，VK2735的口服片劑版本在早期試驗中顯示出令人鼓舞的跡象，28天后減重高達5.3％。 Viking預計將在今年晚些時候啓動口服藥項目的第2階段試驗。
Viking reported an earnings loss of 20 cents per share for the second quarter, beating analyst estimates for a loss of 27 cents per share. Analysts at HC Wainwright reiterated Buy on Thursday with a price target of $90, while Raymond James maintained a Strong Buy and lifted its target to $118.
Viking第二季度每股虧損20美分，超過了分析師預期的每股虧損27美分。HC Wainwright的分析師在週四重申買入，目標價位爲90美元，而Raymond James則維持強烈買入，目標價位上調至118美元。